Skip to main content
TipRanks
Go Ultimate75% OFF

Entrada Therapeutics Inc (TRDA) Stock Statistics & Valuation Metrics

164 Followers

Total Valuation

Entrada Therapeutics Inc has a market cap or net worth of $170.30M. The enterprise value is $123.37M.

Market Cap
$170.30M
Enterprise Value
$123.37M

Share Statistics

Entrada Therapeutics Inc has 39,150,333 shares outstanding. The number of shares has increased by 2.20% in one year.

Shares Outstanding
39,150,333
Owned by Insiders
54.35%
Owned by Institutions
31.38%

Financial Efficiency

Entrada Therapeutics Inc’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -43.69%.

Return on Equity (ROE)
-0.47
Return on Assets (ROA)
-0.38
Return on Invested Capital (ROIC)
-43.69%
Return on Capital Employed (ROCE)
-0.44
Revenue Per Employee
167.24K
Profits Per Employee
-945.72K
Employee Count
152
Asset Turnover
0.07
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Entrada Therapeutics Inc is -1.13. Entrada Therapeutics Inc’s PEG ratio is 0.02.

PE Ratio
-1.13
PS Ratio
42.82
PB Ratio
0.93
Price to FCF
-1.25
Price to Operating Cash Flow
-1.35
PEG Ratio
0.02

Income Statement

In its last fiscal year, Entrada Therapeutics Inc had revenue of 25.42M and earned -143.75M in profits. Earnings per share was -3.47.

Revenue
25.42M
Gross Profit
21.32M
Operating Income
-156.00M
Pretax Income
-142.83M
Net Income
-143.75M
EBITDA
-138.73M
Earnings Per Share (EPS)
-3.47

Cash Flow

In the last 12 months, operating cash flow was -136.32M and capital expenditures -9,000, giving a free cash flow of -136.33M.

Operating Cash Flow
-136.32M
Free Cash Flow
-136.33M
Free Cash Flow per Share
-3.22

Dividends & Yields

Entrada Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―.

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-80.05%
Earnings Yield
-87.56%

Stock Price Statistics

Beta
0.94
52-Week Price Change
-52.56%
50-Day Moving Average
5.42
200-Day Moving Average
8.31
Relative Strength Index (RSI)
40.55
Average Volume (3m)
401.15K

Important Dates

Entrada Therapeutics Inc upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 17, 2027
Ex-Dividend Date
―

Financial Position

Entrada Therapeutics Inc has a current ratio of 12.53, with a Debt / Equity ratio of 16.64%.

Current Ratio
12.53
Quick Ratio
12.53
Debt to Market Cap
0.00
Net Debt to EBITDA
0.28
Interest Coverage Ratio
0.00

Taxes

In its last fiscal year, Entrada Therapeutics Inc paid 924.00K in taxes.

Income Tax
924.00K
Effective Tax Rate
-0.01

Enterprise Valuation

Entrada Therapeutics Inc EV to EBITDA ratio is -0.65, with an EV/FCF ratio of -0.77.

EV to Sales
26.50
EV to EBITDA
-0.65
EV to Free Cash Flow
-0.77
EV to Operating Cash Flow
-0.77

Balance Sheet

Entrada Therapeutics Inc has $193.01M in cash and marketable securities with $47.31M in debt, giving a net cash position of $145.70M.

Cash & Marketable Securities
$193.01M
Total Debt
$47.31M
Net Cash
$145.70M
Net Cash Per Share
$3.72
Tangible Book Value Per Share
$4.68

Margins

Gross margin is 57.48%, with operating margin of -4303.82%, and net profit margin of -4057.98%.

Gross Margin
57.48%
Operating Margin
-4303.82%
Pretax Margin
-4053.16%
Net Profit Margin
-4057.98%
EBITDA Margin
-4081.80%
EBIT Margin
-4053.16%

Analyst Forecast

The average price target for Entrada Therapeutics Inc is $17.75, which is 308.05% higher than the current price. The consensus rating is Strong Buy.

Price Target
$17.75
Price Target Upside
308.05% Upside
Analyst Consensus
Strong Buy
Analyst Count
6
Revenue Growth Forecast
-93.54%
EPS Growth Forecast
-53.55%

Scores

Smart Score
6
AI Score
45